Hyloris Pharmaceuticals SA

HYL

BE0974363955

Pharmaceuticals

Market Closed - Euronext Bruxelles Other stock markets 09:44:01 2023-11-30 am EST			5-day change	1st Jan Change
12.55 ^EUR	+0.40%		-0.40%	+8.19%

Oct. 26	Kye Pharmaceuticals Partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada	CI
Oct. 18	Hyloris Pharmaceuticals’ Pain Relief Drug Gets US FDA Approval; Shares Jump	MT

Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023

September 06, 2023 at 04:00 pm EDT

Hyloris Pharmaceuticals SA reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 1.16 million compared to EUR 1.03 million a year ago. Net loss was EUR 6.63 million compared to EUR 4.94 million a year ago.

Latest news about Hyloris Pharmaceuticals SA

Kye Pharmaceuticals Partners with Hyloris Pharmaceuticals for the Development and Commercialization of Atomoxetine Oral Solution in Canada	Oct. 26	CI
Hyloris Pharmaceuticals’ Pain Relief Drug Gets US FDA Approval; Shares Jump	Oct. 18	MT
Hyloris Pharma wins US FDA approval for pain treatment	Oct. 18	RE
Hyloris Pharmaceuticals SA Announces U.S. FDA Approval of Maxigesic® IV	Oct. 18	CI
Transcript : Hyloris Pharmaceuticals SA, H1 2023 Earnings Call, Sep 07, 2023	Sep. 07	CI
Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023	Sep. 06	CI
Certain Shares of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-JUN-2023.	Jun. 25	CI
Hyloris Pharmaceuticals Wins EUR1 Million Grant to Develop Idiopathic Rhinitis Treatment	Jun. 09	MT
Hyloris Partner Submits Additional Data to US FDA for Non-opioid Pain Treatment	Apr. 18	MT
Transcript : Hyloris Pharmaceuticals SA, 2022 Earnings Call, Mar 16, 2023	Mar. 16	CI
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2022	Mar. 15	CI
Hyloris Partner AFT Pharmaceuticals Signs Licensing, Distribution Deal for Maxigesic IV Pain Treatment	Jan. 24	MT
Hyloris In-Licenses Possible Medication for Hypophosphatemia	Jan. 20	MT
Hyloris Pharmaceuticals SA Expands Its Pipeline with A Product Candidate for A Mineral Deficiency in the Blood (Hypophosphatemia)	Jan. 20	CI
Hyloris Pharmaceuticals Develops New Treatment For Idiopathic Rhinitis	Nov. 23	MT
Hyloris Pharmaceuticals SA Broadens Pipeline with A Nasal Product Candidate for Idiopathic Rhinitis	Nov. 22	CI
Pleco Therapeutics B.V. announced that it has received €4.6 million in funding from Hyloris Pharmaceuticals SA, Oost NL BV	2022	CI
Pleco Therapeutics B.V. announced that it has received funding from Oost NL BV, Hyloris Pharmaceuticals SA	2022	CI
Hyloris Reports Positive Phase 1 Data for HY-004, A Proprietary Tranexamic Acid Oral Mouth Rinse for Bleeding Related to Dental Procedures	2022	CI
Hyloris' Oral Mouth Rinse Shows Controlled Bleeding After Tooth Extraction in Early-stage Trial	2022	MT
Hyloris Pharmaceuticals SA Receives Complete Response Letter from the US Food and Drug Administration on its Application for the US Registration of Maxigesic IV	2022	CI
Hyloris Pharmaceuticals Receives US FDA Request For Additional Information On Maxigesic	2022	MT
Certain Shares of Hyloris Pharmaceuticals SA are subject to a Lock-Up Agreement Ending on 26-JUN-2022.	2022	CI
Hyloris To Start Equity Offering To Raise $17 Million	2022	MT
Hyloris Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2021	2022	CI

Chart Hyloris Pharmaceuticals SA

Duration

Period

More charts

Company Profile

Hyloris Pharmaceuticals SA is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients and the healthcare system. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad proprietary product pipeline that has the potential to offer significant advantages over currently available alternatives. Hyloris Pharmaceuticals SA currently has two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid analgesic for the treatment of pain. The Company's development strategy primarily focuses on the FDA's 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule has already been established.

Sector

Pharmaceuticals

Calendar

2024-01-07 - JPMorgan Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Hyloris Pharmaceuticals SA

Trading Rating :

Investor Rating :

ESG Refinitiv :

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.55EUR

Average target price

19.90EUR

Spread / Average Target

+58.57%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HYLORIS PHARMACEUTICALS SA	+8.19%	384 M $
ELI LILLY AND COMPANY	+61.10%	532 B $
NOVO NORDISK A/S	+48.29%	452 B $
JOHNSON & JOHNSON	-12.61%	366 B $
MERCK & CO., INC.	-8.30%	256 B $
ABBVIE INC.	-12.03%	245 B $
ROCHE HOLDING AG	-18.74%	217 B $
NOVARTIS AG	+1.83%	199 B $
ASTRAZENECA PLC	-9.73%	197 B $
PFIZER, INC.	-40.84%	170 B $

Other Pharmaceuticals